Incyte waves goodbye to longtime CEO Hervé Hoppenot as new appointment raises M&A hopes
Hervé Hoppenot is retiring after 11 years spent growing Incyte from a one-drug operation to a competitive commercial drugmaker. His successor, Bill Meury, comes with a track record of dealmaking.
Hervé Hoppenot is retiring after 11 years spent growing Incyte from a one-drug operation to a competitive commercial drugmaker. His successor, Bill Meury, comes with a track record of dealmaking.
